Insider · CIK 0001914523
Christopher Ogden
Files at CTMX (CytomX Therapeutics, Inc.). First filing Mar 20, 2025, latest Mar 19, 2026.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CTMX: CytomX Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 47Moderate | CytomX Therapeutics, Inc. | $124k 19,323 shares | -6% | +1162% from low-19% from high | |
| 28Weak | CytomX Therapeutics, Inc. | $33k 12,255 shares | -6% | +537% from low-8% from high | |
| 37Weak | CytomX Therapeutics, Inc. | $5,122 8,551 shares | -4% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | CTMX CytomX Therapeutics, Inc. | SOpen-market sale Common Stock | -19,323 | $6.42 | $124k | 296,948 | Mar 19, 2026 |
| Feb 2, 2026 | CTMX CytomX Therapeutics, Inc. | AGrant or award Common Stock | +90,000 | $0.00 | $0 | 316,271 | Feb 4, 2026 |
| Feb 2, 2026 | CTMX CytomX Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +325,000 | $0.00 | $0 | 325,000 | Feb 4, 2026 |
| Sep 26, 2025 | CTMX CytomX Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +78,250 | $0.00 | $0 | 78,250 | Sep 30, 2025 |
| Sep 26, 2025 | CTMX CytomX Therapeutics, Inc. | AGrant or award Performance Stock Units (PSUs)derivative | +39,150 | $0.00 | $0 | 39,150 | Sep 30, 2025 |
| Jun 13, 2025 | CTMX CytomX Therapeutics, Inc. | SOpen-market sale Common Stock | -1,641 | $2.95 | $4,841 | 199,385 | Jun 17, 2025 |
| Jun 13, 2025 | CTMX CytomX Therapeutics, Inc. | MOption exercise Common Stock | +37,500 | $0.00 | $0 | 236,885 | Jun 17, 2025 |
| Jun 16, 2025 | CTMX CytomX Therapeutics, Inc. | SOpen-market sale Common Stock | -10,614 | $2.69 | $29k | 226,271 | Jun 17, 2025 |
| Jun 13, 2025 | CTMX CytomX Therapeutics, Inc. | MOption exercise Performance Stock Unitsderivative | -37,500 | $0.00 | $0 | 0 | Jun 17, 2025 |
| Mar 18, 2025 | CTMX CytomX Therapeutics, Inc. | SOpen-market sale Common Stock | -8,551 | $0.60 | $5,122 | 201,026 | Mar 20, 2025 |
| Feb 4, 2025 | CTMX CytomX Therapeutics, Inc. | AGrant or award Common Stock | +44,000 | $0.00 | $0 | 152,077 | Feb 6, 2025 |
| Feb 4, 2025 | CTMX CytomX Therapeutics, Inc. | AGrant or award Common Stock | +57,500 | $0.00 | $0 | 209,577 | Feb 6, 2025 |
| Feb 4, 2025 | CTMX CytomX Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +225,000 | $0.00 | $0 | 225,000 | Feb 6, 2025 |
| Feb 4, 2025 | CTMX CytomX Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +115,000 | $0.00 | $0 | 115,000 | Feb 6, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.